Table 5.
Antidiabetic medication prescribed for patients with type 2 diabetes mellitus (N = 1167).
| Antidiabetic medication or class of medications | Overall | Preferably prescribed | Underprescribed |
|---|---|---|---|
| (n = 1167) | (n = 222) | (n = 945) | |
| SGLT2i | 129 (11.1) | 129 (58.1) | —— |
| Dapagliflozin | 117 (90.7) | 117 (52.7) | —— |
| Empagliflozin | 12 (9.3) | 12 (5.4) | —— |
| GLP−1 RA | 115 (9.8) | 115 (51.8) | —— |
| Liraglutide | 81 (70.4) | 81 (36.5) | —— |
| Semglutide | 33 (28.7) | 33 (14.9) | —— |
| Dulaglutide | 1 (0.9) | 1 (0.4) | —— |
| Additional antidiabetic agents | |||
| Metformin | 982 (84.1) | 191 (86.0) | 791 (83.7) |
| Insulin | 503 (43.1) | 122 (55.0) | 381 (40.3) |
| DPP−4 inhibitors | 438 (37.5) | 74 (33.3) | 364 (38.5) |
| Sulphonylurea | 381 (32.6) | 67 (30.2) | 314 (33.2) |
| Thiazolidinedione | 19 (1.6) | 6 (2.7) | 13 (1.4) |
Data are presented as frequency (%).
SGLT2i, Sodium–glucose Cotransporter−2 Inhibitors; GLP−1 RA, Glucagon–like Peptide−1 Receptor Agonists; DPP−4, Dipeptidyl peptidase−4.